The California Institute for Regenerative Medicine (CIRM) in San Francisco has awarded US$32 million in grants for research on human induced pluripotent stem (iPS) cell lines. Winners include seven California-based teams that will derive iPS cells from specific tissues to model disease in individual patients. The United States lacks a central iPS-cell bank like those proposed in Japan, but the California initiative will give US researchers access to well-characterized iPS lines for research, says the CIRM.
展开▼
